Lidocaine 5% Medicated Plasters
Use outside of the license of post-herpetic neuralgia for the treatment of localised neuropathic pain with predominance of allodynia and/or hyperalgesia and dysesthesias unresponsive to other neuropathic agents
Lidocaine 5% medicated plasters are recommended outside of their license of post-herpetic neuralgia (PHN) only if all of the following criteria are met;
- Patients present with localised neuropathic pain with predominance of allodynia and/or hyperalgesia and dysesthesias unresponsive to other neuropathic agents and
- Patients are unresponsive to or intolerant of other neuropathic pain agents recommended in NICE/LSCMMG guidelines and
- Treatment is prescribed by clinicians who specialise in the control of pain (e.g. Palliative Care consultants). The medicine should be supplied by the specialist for the duration of the treatment course. Primary care initiation or continuation of treatment is not recommended
Patients already receiving lidocaine plasters in primary care should have the opportunity to continue with treatment until it is deemed clinically appropriate to stop.
This RAG rating is currently under review following publication of the NHS England and NHS Clinical Commissioners guidance document ‘Items which should not routinely be prescribed in primary care: Guidance for CCGs‘ published in November 2017 and maybe subject to change.
Reason for decision: